Necrotizing enterocolitis: old problem with new hope.
ABSTRACT The incidence of necrotizing enterocolitis (NEC) and mortality rate associated with this disease are not decreasing despite more than three decades of intensive research investigation and advances in neonatal intensive care. Although the etiology of NEC is not clearly elucidated, the most accepted hypothesis at present is that enteral feeding in the presence of intestinal hypoxia-ischemia-reperfusion, and colonization with pathogens provokes an inappropriately accentuated inflammatory response by the immature intestinal epithelial cells of the preterm neonate. However, delayed colonization of commensal flora with dysbiotic flora with a predominance of pathologic microorganisms plays a fundamental role in the pathogenesis of NEC. Recent studies have further identified that NEC infants have less diverse flora compared to age-matched controls without NEC. Increased gastric residual volume may be an early sign of NEC. An absolute neutrophil count of <1.5 × 10(9)/L and platelets below 100 × 10(9)/L are associated with an increased risk for mortality and gastrointestinal morbidity. Nonspecific supportive medical management should be initiated promptly. Sudden changes in vital signs such as tachycardia or impending shock may indicate perforation. A recent meta-analysis investigating using probiotics for prevention of NEC with a total of 2176 preterm very low birth weight infants found a success rate of just 1/25. Careful monitoring of the residual volume, and of serious changes in hemograms and vital signs may help in early diagnosis and prediction of when to perform medical or early surgical intervention. In term of prevention, administration of oral probiotics containing Bifidobacterium and Lactobacillus is a simple and safe method that attempts to early establish of commensal flora balance to inhibit pathogenic flora and an inflammatory response.
- [Show abstract] [Hide abstract]
ABSTRACT: It is routine practice in most neonatal intensive care units to measure the volume and color of gastric residuals (GRs) prior to enteral bolus feedings in preterm very low birth weight infants. However, there is paucity of evidence supporting the routine use of this technique. Moreover, owing to the lack of uniform standards in the management of GRs, wide variations exist as to what constitutes significant GR volume, the importance of GR color and frequency of GR evaluation, and the color or volume standards that dictate discarding or returning GRs. The presence of large GR volumes or green-colored residuals prior to feeding often prompts subsequent feedings to be withheld or reduced because of possible necrotizing enterocolitis resulting in delays in enteral feeding. Cessation or delays in enteral feeding may result in extrauterine growth restriction, a known risk factor for poor neurodevelopmental and growth outcomes in preterm very low birth weight infants. Although some neonatal intensive care units are abandoning the practice of routine GR evaluation, little evidence exists to support the discontinuation or continuation of this practice. This review summarizes the current state of GR evaluation and underlines the need for a scientific basis to either support or refute the routine evaluation of GRs.Pediatrics & Neonatology. 01/2014;
- [Show abstract] [Hide abstract]
ABSTRACT: High-mobility group box protein 1 (HMGB1) is a nonhistone nuclear protein that has a dual function. Inside the cell, HMGB1 binds DNA, regulating transcription and determining chromosomal architecture. Outside the cell, HMGB1 activates the innate system and mediates a wide range of physiological and pathological responses. HMGB1 exerts these actions through differential engagement of multiple surface receptors, including Toll-like receptor (TLR)2, TLR4, and receptor for advanced glycation end products (RAGE). HMGB1 is implicated as a late mediator of sepsis and is also involved in inflammatory and autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. Interestingly, HMGB1 was associated with tumor progression, becoming a potential therapeutic target, due to its involvement in the resistance to chemotherapy. Its implication on the pathogenesis of systemic vasculitis and inflammatory bowel diseases has also been evaluated. Moreover, it regulates neuroinflammation after traumatic brain injuries or cerebral infectious diseases. The aim of this review is to analyze these different roles of HMGB1, both in physiological and pathological conditions, discussing clinical and scientific implications in the field of pediatrics. Conclusion: HMGB1 plays a key role in several pediatric diseases, opening new scenarios for diagnostic biomarkers and therapeutic strategies development.European Journal of Pediatrics 05/2014; · 1.98 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Necrotizing enterocolitis (NEC) is one of the most common acquired diseases of the gastrointestinal tract in preterm infants. Some randomized, controlled trials (RCTs) have indicated that probiotics may potentially lower the incidence of NEC and mortality. However, debate still remains about the safety of probiotics and their influence on normal infant growth. We performed this meta-analysis to assess the safety and benefits of probiotic supplementation in preterm infants. We searched in PubMed, Embase, and Cochrane databases for English references, and in Wanfang, VIP, and CNKI databases for Chinese references. Ultimately, 27 RCTs (including 9 Chinese articles) were incorporated into this meta-analysis. Relative risk (RR) and weighted mean difference (WMD) were calculated using a random-effects or fixed-effects model, depending on the data type and heterogeneity. A total of 6655 preterm infants, including the probiotic group (n=3298) and the placebo group (n=3357), were eligible for inclusion in this meta-analysis. For Bell stage ≥I and gestational age <37 weeks, risk of NEC incidence was significantly lower in the probiotic group [RR=0.35, 95% confidence interval (CI)=0.27-0.44, P<0.00001]. For Bell stage ≥II or gestational age <34 weeks, there were likewise significant differences between the probiotic and placebo groups concerning NEC incidence (RR=0.34, 95%CI=0.25-0.48, P<0.00001; and RR=0.39, 95%CI=0.27-0.56, P<0.00001). Risk of death was significantly reduced in the probiotic group (RR=0.58, 95%CI=0.46-0.75, P<0.0001). In contrast, there was no significant difference concerning the risk of sepsis (RR=0.94, 95%CI=0.83-1.06, P=0.31). With respect to weight gain and the age at which infants reached full feeds, no significant differences were found between the probiotic and placebo groups (WMD=1.07, 95%CI=-0.21-2.34, P=0.10; and WMD=-1.66, 95%CI=-3.6-0.27, P=0.09). This meta-analysis has shown that, regardless of gestational age and NEC stage, probiotic supplementation could significantly reduce the risk of NEC in preterm infants. Analysis also indicated that such supplementation did not increase the incidence risk of sepsis or of mortality. Finally, the study showed that probiotic supplementation may have no adverse effect on normal feeding and growth.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 08/2014; · 1.08 Impact Factor
Necrotizing Enterocolitis: Old Problem with
Shu-Fen Wua,b, Michael Caplanc, Hung-Chih Lina,d,*
aDepartment of Pediatrics, China Medical University Hospital, China Medical University, Taichung, Taiwan
bSchool of Medicine, China Medical University, Taichung, Taiwan
cThe University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637, USA
dSchool of Chinese Medicine, China Medical University, Taichung, Taiwan
Received Jun 28, 2011; received in revised form Sep 23, 2011; accepted Oct 12, 2011
The incidence of necrotizing enterocolitis (NEC) and mortality rate associated with this disease
are not decreasing despite more than three decades of intensive research investigation and
advances in neonatal intensive care. Although the etiology of NEC is not clearly elucidated, the
most accepted hypothesis at present is that enteral feeding in the presence of intestinal
hypoxia-ischemia-reperfusion, and colonization with pathogens provokes an inappropriately
accentuated inflammatory response by the immature intestinal epithelial cells of the preterm
neonate. However, delayed colonization of commensal flora withdysbiotic flora with a predomi-
studies havefurther identifiedthatNECinfants havelessdiversefloracomparedto age-matched
controls without NEC.IncreasedgastricresidualvolumemaybeanearlysignofNEC.An absolute
neutrophil count of <1.5 ? 109/L and platelets below 100 ? 109/L are associated with an
increased risk for mortality and gastrointestinal morbidity. Nonspecific supportive medical
management should be initiated promptly. Sudden changes in vital signs such as tachycardia or
impending shock may indicate perforation. A recent meta-analysis investigating using probiotics
for prevention of NEC with a total of 2176 preterm very low birth weight infants found a success
and vital signs may help in early diagnosis and prediction of when to perform medical or early
surgical intervention. In term of prevention, administration of oral probiotics containing Bifido-
bacterium and Lactobacillus is a simple and safe method that attempts to early establish of
commensal flora balance to inhibit pathogenic flora and an inflammatory response.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
* Corresponding author. Department of Pediatrics, China Medical University Hospital, China Medical University, No. 2 Yu-Der Road,
Taichung 404, Taiwan.
E-mail address: firstname.lastname@example.org (H.-C. Lin).
1875-9572/$36 Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
Available online at www.sciencedirect.com
journal homepage: http://www.pediatr-neonatol.com
Pediatrics and Neonatology (2012) 53, 158e163
Necrotizing enterocolitis (NEC), an acute inflammatory
necrosis of the intestinal tract, is the most common
acquired gastrointestinal and surgical emergency for
preterm very low-birth weight (VLBW) infants in the
neonatal intensive care unit (NICU).1Despite more than
three decades of intensive research investigation, little
progress has been made in the prevention and treatment of
NEC; in fact, despite advances in NICU care throughout the
world, the incidence and mortality associated with this
disease is not decreasing.2,3
The incidence of NEC is inversely proportional to birth
weight (BW), with NEC affecting 11.5% of infants weighing
401 to 750 g, 9% of infants weighing 751 to 1000 g, 6% of
infants weighing 1001 to 1250 g, and 4% of infants weighing
1251 to 1500 g.4Two sets of national data showed that the
incidence of NEC was relatively low in Taiwan (about 7%)5,6;
however, since fatality is a competing variable for NEC,
true incidence might be underestimated because the
mortality rate for VLBW infants was higher in Taiwan than in
3. Etiology and pathogenesis
NEC is a complex disease and the etiology has not been
clearly elucidated. Multiple factors appear to contribute to
the pathogenesis:immaturity of multiple intestinal func-
tions includes gastrointestinal dysmotility, impaired diges-
tive capacity, altered regulation of intestinal blood flow,
barrier dysfunction, altered anti-inflammatory control, and
impaired host defense. It has been shown in experimental
systems that feeding, intestinal ischemia, and bacteria
could cause mucosal injury,7e9and in preterm infants with
an altered pattern of bacterial colonization,10provoke an
inappropriate accentuated proinflammatory response that
results in inflammatory necrosis of the bowel,11and in some
cases, the systemic inflammatory response syndrome.12,13
It has been suggested that an unfavorable balance
between commensal and pathogenic bacteria is present in
the VLBW intestinal tract, and that this triggers a series of
cellular events that results in the pathogenesis of NEC.14,15
More recent studies using high-throughput molecular tech-
niques have identified differences in the diversity of
organisms present, and in one report it appeared that NEC
patients had lower diversity compared to age-matched
controls without NEC.16
Commensal bacteria can regulate the expression of
genes important for barrier function, digestion, and
angiogenesis.17In vitro studies have demonstrated that
many species of commensal bacteria have the ability to
dampen the inflammatory response through inhibition
(NF-kB).18,19Endotoxin is known to bind to and activate
Toll-like receptor 4 (TLR4), and TLR4 mRNA expression has
been documented in fetal human intestine20
increased in formula-fed and hypoxia-stressed rats.21When
lipopolysaccharide binds to TLR4, a series of chaperone and
signal transduction molecules are activated, which result in
NF-kB translocation from cytoplasm to the nucleus where
this important transcription factor activates the gene
Following the activation of proinflammatory gene expres-
perturbation of tight junctional proteins and complexes,
increased mucosal permeability, bacterial translocation,
alterations of vascular tone and microcirculation, and
additional neutrophil infiltration and accumulation.23e27
Thus,dysbiotic flora with a predominance of pathologic
microorganisms plays a fundamental role in the pathology
of NEC; animal studies have shown that severe NEC could
not be induced without the pathologic flora.28It is likely
that the balance of pro- and anti-inflammatory signaling is
critical in maintaining intestinal homeostasis. Nonetheless,
it is hypothesized that the immature intestine responds to
injury with excessive inflammation and that this contrib-
utes to the final common pathway in the pathogenesis of
NEC.29,30Many pro- and anti-inflammatory mediators are
involved in the pathogenesis of NEC based on animal or
human studies. Proinflammatory compounds that are up
regulated in NEC include platelet activating factor, tumor
necrosis factor, nitric oxide, interleukins (IL), such as IL-1b,
IL-6, IL-8, IL-12, and IL-18, and endothelin-1, leukotrienes,
thromboxanes, and oxygen-free radicals.31e39Several anti-
inflammatory compounds down regulate intestinal inflam-
mation and these include prostacyclin, nitric oxide, several
growth factors such as epidermal growth factor, heparin-
binding epidermal growth factor, and insulin-like growth
factor, erythropoietin, IL-11, glutamine, and arginine.40e45
In addition, animal studies have shown that neonates have
an impaired ability to prevent NF-kB from entering the
nucleus in intestinal epithelial cells and activating the
mediators.17e19In summary, these results suggest that the
neonatal balance of the inflammatory response may be
weighted towards the proinflammatory side and more likely
to result in the pathologic outcome of NEC.
Diagnosis of NEC is suspected when the characteristic
clinical features of abdominal distention, increased gastric
residual volume or frank emesis, and rectal bleeding are
present, and is confirmed by abdominal radiographic
evidence of pneumatosis intestinalis or portal venous air.
Increased residual gastric volume might be an early sign of
NEC. Radiological findings vary by gestational age; intra-
mural gas was detected in infants of ?37 weeks’ gestational
age with NEC, but was only present in 29% of those of ?26
weeks’ gestational age.46Abdominal ultrasonography is
a newer technique to aid in the diagnosis of NEC47and may
be more sensitive than abdominal radiography in detecting
bowel necrosis and alterations in bowel wall perfusion as
include central echogenic focus of bowel wall and a hypo-
echoic rim (the pseudo-kidney sign) that indicate necrotic
bowel and imminent perforation. Ultrasonography also can
Necrotizing enterocolitis 159
detect air bubbles in liver parenchyma and in the portal
venous system, and resolution of these findings is found to
correlate with safe re-initiation of enteral feedings.47
5. Laboratory evaluation
Sepsis evaluation should be performed when NEC is sus-
pected because 20% to 30% of infants will become bacter-
emic.49An absolute neutrophil count <1.5 ? 109/L is
associated with a poor prognosis.50In addition, a platelet
count <100 ? 109/L is associated with an increased risk for
mortality and gastrointestinal morbidity, and it is suggested
that declining platelet counts correlate with necrotic bowel
and worsening disease, whereas a subsequent rise in
platelet countsoften signals
increases in C-reactive protein and plasma lactate level
may predict progression of definite NEC to surgery or death
in preterm neonates.52Additional laboratory abnormalities,
including persistent hyponatremia (serum sodium <130
meq/L), hyperglycemia, and metabolic acidosis are asso-
ciated with worsening disease.53
6. Differential diagnosis
Conditions such as sepsis, viral enteritis, and cow’s milk
protein allergy are difficult to distinguish from early signs of
NEC. A surgical disorder that closely mimics NEC is the
spontaneous intestinal perforation that typically presents
early in the neonatal course, and demonstrates free air on
a radiograph without evidence of pneumatosis intestinalis.
Other rare surgical conditions, including ileal atresia,
intussusception, are often mistaken for NEC.
7. Medical management
Nonspecific supportive management should be initiated
promptly when NEC is suspected, but even with early
medical management, the progress of disease may still not
alter. Supportive care measures are aimed to limit the
progression of disease, and include discontinuation of
intermittent nasogastric suction, fluid resuscitation, blood
pressure support, and correction of acidosis, electrolyte
therapy and its duration in these patients should be
adjusted according to illness severity assigned by Bell’s
staging,54the presence of peritonitis and/or perforation,
and the presence of sepsis.
8. Surgical intervention
Infants with NEC require surgical intervention when
necrosis extends through the bowel wall and results in
perforation. Additional surgical indications include perito-
nitis, the presence of an abdominal mass, ascites, intestinal
obstruction fixed dilated loop, or unremitting clinical
deterioration for an extended period of time.55A sudden
change in vital signs, such as tachycardia, hypothermia, or
impending shock, might be a sign of perforation.Surgical
intervention with primary peritoneal drainage (PPD) or
laparotomy has been debated for several years in a multi-
center controlled study56of 117 infants (<34 weeks
gestation) with perforated NEC to evaluate the benefit of
PPD versus laparotomy, no difference was noted between
PPD and laparotomy in mortality rate (34.5% vs. 35.5%), the
need for total parenteral nutrition (47.2% vs. 40%, respec-
tively) at 90 days postoperatively, or length of hospital stay.
The current standard of care allows treatment based upon
the judgment of the attending pediatric surgeon and
improvement with stool passage spontaneously after PPD
may begin feedings without a contrast medium study and
never require a subsequent surgical procedure. In most
instances, laparotomy is indicated for patients who fail to
Complications of NEC include sepsis, meningitis, perito-
nitis, abscess formation, disseminated intravascular coag-
ulation, hypotension, shock, and respiratory and renal
failure, and can occur during the acute stage of the disease
and immediate postrecovery stage. Late complications are
intestinal narrowing and short bowel syndrome, and rare
complications include enterocele, enterocolic fistula, and
Intestinal strictures are common, occur in 9% to 36% of
infants, and are unrelated to the severity of NEC, the
presence of pneumatosis intestinalis, or gestational age.57
The majority of strictures occur in the colon, although
the ileum and jejunum also are affected, and strictures at
multiple sites are common.58Strictures typically develop
within 2 to 3 months of the acute episode but are some-
times detected as late as 20 months after the diagnosis.
Because of the high risk of stricture formation, the intes-
tinal contrast studies can be helpful in post-NEC patients if
feeding intolerance develops.
Mortality of infants with NEC was highest in infants of <27
weeks’ gestational age and in those with extensive
involvement of the small and large bowel.57,59Data from
the Vermont Oxford Network60demonstrated that the risk
of NEC and mortality decreased with increasing BW as
follows: BW 1251 to 1500 g, 3% risk of NEC, 16% died; BW
1001 to 1250 g, 6% risk of NEC, 21% died; BW 751 to 1000 g,
9% risk of NEC, 29% died; and BW 501 to 750 g, 12% risk of
NEC, 42% died. The majority of infants who had not had
extensive intestinal resection had normal gastrointestinal
function at age 1 to 10 years.
The Neonatal Research Network of National Institute of
Child Health and Human Development, showed that infants
of BW <1000 g who required surgical care were more likely
to have significant growth delay and poorer developmental
outcome at 18 to 22 months compared to those with-
outNEC61; the VLBW infants who were less sick with NEC
and only treated medically did not differ in growth or
developmental testing compared to those without NEC.62In
a systematic review,63NEC infants were twice as likely to
160 S.-F. Wu et al
be developmentally impaired compared to age-matched
controls, with increased risk for cerebral palsy, cognitive
impairment, and severe visual impairment.
Given that the etiology of NEC is not clearly elucidated,
specific interventions to prevent or treat this disease are
lacking. Furthermore, NEC frequently progresses from early
signs of intestinal inflammation to extensive necrosis within
a matter of hours; thus, the development of preventive
strategies is indicated. Several approaches to prevent the
initiation of NEC have been attempted, but, for a variety
reasons, only breast milk feeding has attained consensus as
standard of care.64Studies with preliminary success include
IgA supplementation, intravenous dexamethasone, enteral
antibiotics, polyunsaturated fatty acid supplementation,
lactoferrin, and arginine supplementation; however, due to
the inability to reproduce results and potential toxicities,
these approaches are not used routinely.
Probiotics are commensal bacteria that confer beneficial
effects to the host. They act on multiple mechanisms and
can promote maturation of intestinal barrier function,65
regulate apoptosis,66reduce growth and adherence of
potentially pathogenic organisms,67enhance the produc-
tion of anti-inflammatory cytokines68and secretory IgA,69
attenuate the production nitric oxide,70and increase
different pathways, and since the etiology and pathogen-
esis of NEC is multifactorial, it is unlikely that a single agent
will effectively prevent the initiation of disease (Figure 1).
Clinical observations and animal studies suggest that
delayed colonization of commensal flora observed in
preterm infants could contribute to the development of
Caplan and Butel showed that Bifidobacteria
supplementation in neonatal rat and quail models result in
intestinal colonization and subsequent reduction in NEC-
like lesions.72,73In reviewing the literature, there are
many clinical trials using probiotics in preterm VLBW
infants to prevent NEC or other outcomes. Of the studies,
only eleven randomized control trials could provide data to
examine the role of probiotics in the prevention of NEC.
From a total of 2176 neonates observed in these studies,
the number of infants need to be treated with probiotics to
prevent one case of NEC was 25; the relative risk was 0.35
(95% confidence interval: 0.23e0.55) in a recent meta-
analysis (Figure 2).74Furthermore, a follow-up study at
corrected age 2 years showed that oral probiotics given to
premature VLBW infants after age 1 week to reduce the
incidence of NEC did not affect the growth and neuro-
developmental and sensory outcomes.75Thus, use of pro-
biotics in VLBW infants is relatively safe on short-term and
probiotics containing Bifidobacterium and Lactobacillus is
Effectiveness of Probiotics: rational of biologic pathomechanisms.
involing 2176 neonates.
Data on definite NEC were reported by all 11 trials
Necrotizing enterocolitis 161
a simple, safe, and noninvasive method that attempts early
establishment of commensal flora balance to inhibit patho-
genic flora and the inflammatory response.
The authors thank Drs W. B. Dobyns, W. Weiss and A. Sla-
votinek for their critical review of the manuscript.
1. Henry MC, Lawrence Moss R. Surgical therapy for necrotizing
enterocolitis: Bringing evidence to the bedside. Semin Pediatr
2. Hsueh W, de Plaen IG, Caplan MS, Qu XW, Tan XD, Gonzalez-
Crussi F. Neonatal necrotizing enterocolitis clinical aspects,
experiment models and pathogenesis. World J Pediatr 2007;3:
3. Holman RC, Stoll BJ, Curns AT, Yorita KL, Steiner CA,
Schonberger LB. Necrotising enterocolitis hospitalisations
among neonates in the United States. Paediatr Perinat Epi-
4. Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-blocker
therapy and higher incidence of necrotizing enterocolitis in
very low birth weight infants. Pediatrics 2006;117:e137e42.
5. Chen CH, Hsiao ML, Huang CB. Development and maintenance
of national data bank for very low birth weight infants. Annual
Meeting of Taiwan Pediatric Association; 2007.
6. Year book of premature baby foundation of Taiwan 2007.
7. Caplan MS, Jilling T. New concepts in necrotizing enterocolitis.
Curr Opin Pediatr 2001;13:111e5.
8. Noda T, Iwakiri R, Fujimoto K, Matsuo S, Aw TY. Programmed
cell death induced by ischemia-reperfusion in rat intestinal
mucosa. Am J Physiol 1998;274:G270e6.
9. Claud EC, Walker WA. Hypothesis: inappropriate colonization
of the premature intestine can cause neonatal necrotizing
enterocolitis. FASEB J 2001;15:1398e403.
10. Hoy CM, Wood CM, Hawkey PM, Puntis JW. Duodenal microflora
in very-low-birth-weight neonates and relation to necrotizing
enterocolitis. J Clin Microbiol 2000;38:4539e47.
11. Nanthakumar NN, Fusunyan RD, Sanderson I, Walker WA.
Inflammation in the developing human intestine: A possible
pathophysiologic contribution to necrotizing enterocolitis.
Proc Natl Acad Sci U S A 2000;97:6043e8.
12. Markel TA, Crisostomo PR, Wairiuko GM, Pitcher J, Tsai BM,
Meldrum DR. Cytokines in necrotizing enterocolitis. Shock
13. Caicedo RA, Schanler RJ, Li N, Neu J. The developing intestinal
ecosystem: impactions for the neonate. Pediatr Res 2005;58:
14. Hoy C, Millar MR, MacKay P, Godwin PG, Langdale V, Levene MI.
Quantitative changes in faecal microflora preceding necro-
tizing enterocolitis in premature neonates. Arch Dis Child
15. Gewolb IH, Schwalbe RS, Taciak VL, Harrison TS, Panigrahi P.
Stool microflora in extremely low birth weight infants. Arch Dis
Child Fetal Neonatal Ed 1999;80:F167e73.
16. Wang Y, Hoenig JD, Malin KJ, Qamar S, Petrof EO, Sun J. 16S
rRNA gene-based analysis of fecal microbiota from preterm
infants with and without necrotizing enterocolitis. ISME J 2009;
17. Wallace TD, Bradley S, Buckley ND, Green-Johnson JM. Inter-
actions of lactic acid bacteria with human intestinal epithelial
cells: effects on cytokine production. J Food Prot 2003;66:
18. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut
cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol
19. Collier-Hyams LS, Sloane V, Batten BC, Neish AS. Cutting edge:
Bacterial modulation of epithelial signaling via changes in
neddylation of cullin-1. J Immunol 2005;175:4194e8.
20. Fusunyan RD, Nanthakumar NN, Baldeon ME, Walker WA.
Evidence for an innate immune response in the immature
human intestine: toll-like receptors on fetal enterocytes.
Pediatr Res 2001;49:589e93.
21. Jilling T, Simon D, Lu J, et al. The roles of bacteria and tlr4 in
rat and murine models of necrotizing enterocolitis. J Immunol
22. Akira S, Yamamoto M, Takeda K. Role of adapters in toll-like
receptor signalling. Biochem Soc Trans 2003;31:637e42.
23. Kim JM, Eckmann L, Savidge TC, Lowe DC, Wittho ¨ft T,
Kagnoff MF. Apoptosis of human intestinal epithelial cells after
bacterial invasion. J Clin Invest 1998;102:1815e23.
24. Lu J, Caplan MS, Saraf AP, et al. Platelet-activating factor-
induced apoptosis is blocked by Bcl-2 in rat intestinal epithe-
lial cells. Am J Physiol Gastrointest Liver Physiol 2004;286:
25. Guy-Grand D, DiSanto JP, Henchoz P, Malassis-Se ´ris M,
Vassalli P. Small bowel enteropathy: role of intraepithelial
lymphocytes and of cytokines (IL-12, IFN-gamma, TNF) in the
induction of epithelial cell death and renewal. Eur J Immunol
26. Jarry A, Bossard C, Bou-Hanna C, et al. Mucosal IL-10 and TGF-
beta play crucial roles in preventing LPS-driven, IFN-gamma-
mediated epithelial damage in human colon explants. J Clin
27. Kaufman HL, Swartout BG, Ho ¨rig H, Lubensky I. Combination
interleukin-2 and interleukin-12 induces severe gastrointes-
tinal toxicity and epithelial cell apoptosis in mice. Cytokine
28. Caplan MS, Hedlund E, Adler L, Hsueh W. Role of asphyxia and
feeding in a neonatal rat model of necrotizing enterocolitis.
Pediatr Pathol Lab Med 1994;14:1017e28.
29. Lin PW, Stoll BJ. Necrotising enterocolitis. Lancet 2006;368:
30. Grave GD, Nelson SA, Walker WA, et al. New therapies and
preventive approaches for necrotizing enterocolitis: report
of a research planning workshop. Pediatr Res 2007;62:
31. Mishima S, Xu D, Lu Q, Deitch EA. Bacterial translocation is
inhibited in inducible nitric oxide synthase knockout mice after
endotoxin challenge but not in a model of bacterial over-
growth. Arch Surg 1997;132:1190e5.
32. Upperman JS, Potoka D, Grishin A, Hackam D, Zamora R,
Ford HR. Mechanisms of nitric oxide-mediated intestinal
barrier failure in necrotizing enterocolitis. Semin Pediatr Surg
33. Caplan MS, Sun XM, Hseuh W, Hageman JR. Role of platelet
activating factor and tumor necrosis factor-alpha in neonatal
necrotizing enterocolitis. J Pediatr 1990;116:960e4.
34. Sharma R, Tepas JJ 3rd, Hudak ML, et al. Neonatal gut barrier
and multiple organ failure: role of endotoxin and proin-
flammatory cytokines in sepsis and necrotizing enterocolitis.
J Pediatr Surg 2007;42:454e61.
35. Halpern MD, Holubec H, Dominguez JA, et al. Up-regulation of
IL-18 and IL-12 in the ileum of neonatal rats with necrotizing
enterocolitis. Pediatr Res 2002;51:733e9.
36. Miller MJ, Clark DA. Profile and sites of eicosanoid release in
experimental necrotizing enterocolitis. Adv Prostaglandin
Thromboxane Leukot Res 1989;19:556e9.
37. Hyman PE, Abrams CE, Zipser RD. Enhanced urinary immuno-
reactive thromboxane in neonatal necrotizing enterocolitis.
162S.-F. Wu et al
A diagnostic indicator of thrombotic activity. Am J Dis Child
38. Harris MC, D’Angio CT, Gallagher PR, Kaufman D, Evans J,
Kilpatrick L. Cytokine elaboration in critically ill infants with
bacterial sepsis, necrotizing entercolitis, or sepsis syndrome:
correlation with clinical parameters of inflammation and
mortality. J Pediatr 2005;147:462e8.
39. Clark DA, Fornabaio DM, McNeill H, Mullane KM, Caravella SJ,
Miller MJ. Contribution of oxygen-derived free radicals to
experimental necrotizing enterocolitis. Am J Pathol 1988;130:
40. Clark JA, Lane RH, Maclennan NK, et al. Epidermal growth
factor reduces intestinal apoptosis in an experimental model
of necrotizing enterocolitis. Am J Physiol Gastrointest Liver
41. Edelson MB, Bagwell CE, Rozycki HJ. Circulating pro- and
counterinflammatory cytokine levels and severity in necro-
tizing enterocolitis. Pediatrics 1999;103:766e71.
42. Ozen S, Akisu M, Baka M, et al. Insulin-like growth factor atten-
induced intestinal injury. Biol Neonate 2005;87:91e6.
43. Nadler EP, Stanford A, Zhang XR, et al. Intestinal cytokine gene
expression in infants with acute necrotizing enterocolitis:
interleukin-11 mRNA expression inversely correlates with
extent of disease. J Pediatr Surg 2001;36:1122e9.
44. Harris MC, Costarino AT Jr, Sullivan JS, et al. Cytokine eleva-
tions in critically ill infants with sepsis and necrotizing
enterocolitis. J Pediatr 1994;124:105e11.
45. Becker RM, Wu G, Galanko JA, et al. Reduced serum amino
acid concentrations in infants with necrotizing enterocolitis.
J Pediatr 2000;137:785e93.
46. Sharma R, Hudak ML, Tepas JJ 3rd, et al. Impact of gestational
age on the clinical presentation and surgical outcome of
necrotizing enterocolitis. J Perinatol 2006;26:342e7.
47. Silva CT, Daneman A, Navarro OM, et al. Correlation of sono-
graphic findings and outcome in necrotizing enterocolitis.
Pediatr Radiol 2007;37:274e82.
48. Faingold R, Daneman A, Tomlinson G, et al. Necrotizing
enterocolitis: assessment of bowel viability with color doppler
US. Radiology 2005;235:587e94.
49. Kliegman RM, Fanaroff AA. Necrotizing enterocolitis. N Engl J
50. Neu J. Necrotizing enterocolitis: the search for a unifying
pathogenic theory leading to prevention. Pediatr Clin North
51. Kenton AB, O’Donovan D, Cass DL, et al. Severe thrombocy-
topenia predicts outcome in neonates with necrotizing
enterocolitis. J Perinatol 2005;25:14e20.
52. Pourcyrous M, Korones SB, Yang W, Boulden TF, Bada SH.
C-reactive protein in the diagnosis, management, and prog-
nosis of neonatal necrotizing enterocolitis. Pediatrics 2005;
53. Ha ¨llstro ¨m M, Koivisto AM, Janas M, Tammela O. Laboratory
parameters predictive of developing necrotizing enterocolitis
in infants born before 33 weeks of gestation. J Pediatr Surg
54. Kliegman RM, Walsh MC. Neonatal necrotizing enterocolitis:
pathogenesis, classification, and spectrum of illness. Curr
Probl Pediatr 1987;17(4):213e88.
55. Tepas JJ 3rd, Sharma R, Leaphart CL, Celso BG, Pieper P,
Esquivia-Lee V. Timing of surgical intervention in necrotizing
enterocolitis can be determined by trajectory of metabolic
derangement. J Pediatr Surg 2010;45:310e3.
56. Moss RL, Dimmitt RA, Barnhart DC, et al. Laparotomy versus
peritoneal drainage for necrotizing enterocolitis and perfora-
tion. N Engl J Med 2006;354:2225e34.
57. Horwitz JR, Lally KP, Cheu HW, Vazquez WD, Grosfeld JL,
Ziegler MM. Complications after surgical intervention for
necrotizing enterocolitis: a multicenter review. J Pediatr Surg
58. Schimpl G, Ho ¨llwarth ME, Fotter R, Becker H. Late intestinal
strictures following successful
enterocolitis. Acta Paediatr Suppl 1994;396:80e3.
59. Fasoli L, Turi RA, Spitz L, Kiely EM, Drake D, Pierro A. Necro-
tizing enterocolitis: extent of disease and surgical treatment.
J Pediatr Surg 1999;34:1096e9.
60. Fitzgibbons SC, Ching Y, Yu D, et al. Mortality of necrotizing
enterocolitis expressed by birth weight categories. J Pediatr
61. Hintz SR, Kendrick DE, Stoll BJ, Vohr BR, Fanaroff AA. Neuro-
developmental and growth outcomes of extremely low birth
weight infants after necrotizing enterocolitis. Pediatrics 2005;
62. Rees CM, Pierro A, Eaton S. Neurodevelopmental outcomes of
neonates with medically and surgically treated necrotizing
enterocolitis. Arch Dis Child Fetal Neonatal Ed 2007;92:
63. Schulzke SM, Deshpande GC, Patole SK. Neurodevelopmental
outcomes of very low-birth-weight infants with necrotizing
enterocolitis: a systematic review of observational studies.
Arch Pediatr Adolesc Med 2007;161:583e90.
64. McGuire W, Anthony MY. Donor human milk versus formula for
preventing necrotizing enterocolitis
systematic review. Arch Dis Child Fetal Neonatal Ed 2003;88:
65. Hooper LV, Gordon JI. Commensal host-bacterial relationships
in the gut. Science 2001;292:1115e8.
66. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced
apoptosis in intestinal epithelial cells. J Biol Chem 2002;277:
67. Neu J, Douglas-Escobar M, Lopez M. Microbes and the devel-
oping gastrointestinal tract. Nutr Clin Pract 2007;22:174e82.
68. Matsumoto M, Benno Y.
production in the gut from the consumption of probiotic yogurt
containing Bifidobacterium animalis subsp. Lactis LKM512.
Biosci Biotechnol Biochem 2006;70:1287e92.
69. Bakker-Zierikzee AM, Tol EA, Kroes H, Alles MS, Kok FJ,
Bindels JG. Faecal siga secretion in infants fed on pre- or
probiotic infant formula. Pediatr Allergy Immunol 2006;17:
70. Tejada-Simon MV, Ustunol Z, Pestka JJ. Ex vivo effects of
lactobacilli, streptococci, and bifidobacteria ingestion on
cytokine and nitric oxide production in a murine model. J Food
71. Kodali VP, Sen R. Antioxidant and free radical scavenging
activities of an exopolysaccharide from a probiotic bacterium.
Biotechnol J 2008;3:245e51.
72. Caplan MS, Miller-Catchpole R, Kaup S, et al. Bifidobaterial
enterocolitis in a neonatal rat model. Gastroenterology 1999;
73. Butel MJ, Roland N, Hibert A, et al. Clostridial pathogenicity in
experimental necrotising enterocolitis in gnotobiotic quails
and protective role of bifidobacteria. J Med Microbiol 1998;47:
74. Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-
analysis of probiotics for preventing necrotizing enterocolitis
in preterm neonates. Pediatrics 2010;125:921e30.
75. Chou IC, Kuo HT, Chang JS, et al. Lack of effects of oral pro-
biotics on growth and neurodevelopmental outcomes in
preterm very low birth weight infants. J Pediatr 2010;156:
the incidence ofnecrotizing